癃闭舒联合多沙唑嗪治疗肾虚血瘀型良性前列腺增生的临床研究  

Longbishu Capsule combined with mesylate doxazosin: An efficacious therapy for benign prostatic hyperplasia

作　　者：常德贵[1,2] 李广森[1] 彭成华 俞旭君[2] 张培海[1] 毕明帅 陈帝昂[1] 尤耀东[4] 杨兴智[5] 

机构地区：[1]成都中医药大学附属医院泌尿男科,四川成都610072 [2]成都中医药大学第二附属医院男科,四川成都610041 [3]成都市龙泉驿区中医院外科,四川成都610100 [4]成都中医药大学,四川成都610075 [5]重庆市中医院泌尿外科,重庆400021

出　　处：《中华男科学杂志》2015年第2期165-169,共5页National Journal of Andrology

基　　金："十一五"国家科技支撑计划(2007BAI20B044);四川省人事厅课题:2007年省学术和技术带头人培养资金(2008-B-RST-01)~~

摘　　要：目的:研究癃闭舒胶囊联合甲磺酸多沙唑嗪片治疗肾虚血瘀型良性前列腺增生(BPH)的临床疗效及安全性。方法:采用随机、对照、双盲双模拟的方法,将60例肾虚血瘀型BPH患者分为治疗组(甲磺酸多沙唑嗪片联合癃闭舒胶囊)和对照组(甲磺酸多沙唑嗪片联合癃闭舒胶囊安慰剂)各30例,治疗6个月后比较两组治疗前后国际前列腺症状评分(IPSS)、生活质量(QOL)评分、中医症状评分及最大尿流率(Qmax)的变化。结果:治疗组临床治愈5例、显效13例、有效9例、无效1例,脱落2例,总有效率96.4%;对照组临床治愈2例、显效8例、有效10例、无效7例,剔除3例,总有效率74.1%。治疗后两组患者IPSS、中医证候评分及Qmax均较治疗前有明显改善,治疗组改善程度明显优于对照组,治疗组、对照组治疗后IPSS评分分别为(15.22±2.98)、(18.15±5.88)分,两者比较有显著差异(P<0.05),Qmax分别为(13.56±2.26)、(11.78±2.97)ml/s,两者比较有显著差异(P<0.05),中医证候评分分别为(6.18±2.13)、(9.52±3.15)分,两者比较有显著差异(P<0.05)。其中治疗组和对照组治疗前QOL评分有差异(P=0.038),无法再进行两组治疗后QOL评分比较。结论:癃闭舒胶囊联合甲磺酸多沙唑嗪治疗BPH临床安全有效,可以作为治疗该病的一种良好选择。Objective： To assess the clinical effect and safety of the Chinese medicine Longbishu Capsule combined with mesy- late doxazosin in the treatment of benign prostatic hyperplasia （BPH） of the kidney deficiency and blood stagnation type. Methods ： This was a randomized, double-blind, double-simulation control study. We equally assigned 60 men diagnosed with BPH of the kidney deficiency and blood stagnation type to an experimental and a control group, the former treated with mesylate doxazosin plus Longbishu Capsule and the latter with mesylate doxazosin plus placebo. We compared the International Prostate Symptom Score （IPSS） , quality of life （QOL）, Chinese symptom score （CSS）, maximal urinary flow rate （Qmax）, and prostate volume between the two groups of pa- tients before and after 6 months of medication. Results ： After treatment, there were 5 cured cases, 13 markedly effective cases, 9 effective cases, 1 ineffective case, and 2 eliminated cases in the experimental group, as compared with 2 cured cases, 8 markedly effec- tive cases, 10 effective eases, 7 ineffective cases, and 3 eliminated cases in the control group. The total effectiveness rate was obviously higher in the former （96.4%） than in the latter （74.1%）. IPSS, Qmax, and CSS were improved in both of the groups after medication, even more significantly in the experimental than in the control group （ IPSS ： 15.22±2.98 vs 18.15 ± 5.88, P 〈 0.05 ; Qmax ： [13.56±2.26] ml/svs [11.78±2.97] ml/s, P〈0.05; CSS： 6.18 ±2.13 vs9.52±3.15, P〈0.05）. Because of the difference in the QOL score between the two groups at the baseline （ P = 0. 038 〈 0.05 ） , no more comparison was made in this aspect after treatment. Conclusion ： The eombination of Longbishu Capsule with mesylate doxazosin is safe and effeetive for the treatment of BPH.

关 键 词：良性前列腺增生症 癃闭舒 多沙唑嗪 

分 类 号：R697.33[医药卫生—泌尿科学]